CD19 and Miyoshi myopathy: Garfall et al. reported that the CD19-targeted CAR-T cell therapy (CTL019) infusion led to a durable complete response in an advanced refractory MM patient after a high-dose of melphalan treatment and autologous stem cell transplantation (ASCT) [7].